PAHO and Gilead Agreement Paves Way for Semi-Annual HIV Injection in Brazil
An agreement signed Tuesday between Gilead Sciences and the Pan American Health Organization (PAHO) establishes a framework for 14 countries across Latin America and the Caribbean to negotiate access to lenacapavir, a twice-yearly injectable medication designed for HIV pre-exposure prophylaxis (PrEP), according to reporting published by ICL Notícias and Jornal de Brasília.
- Lenacapavir is administered subcutaneously every six months, offering an alternative to daily oral PrEP regimens.
- Brazil is among the 14 regional nations included in the PAHO framework because it was excluded from Gilead’s prior voluntary licensing agreements with generic manufacturers.
- Clinical authorization requires subsequent pricing approval from the Brazilian regulatory body CMED and evaluation by the health technology assessment commission Conitec before public system adoption.
Regulatory Status and Path to the Brazilian Unified Health System
While the agreement opens a formal procurement channel, the announcement does not establish pricing, volume allocations, or a concrete delivery schedule. According to Jornal de Brasília, national governments must first elect to participate in the initiative before individual supply terms are negotiated. In January, the Brazilian Health Regulatory Agency (Anvisa) approved the trade name Sunlenca as a PrEP option for adults and adolescents weighing at least 35 kilograms. Commercial distribution across the country remains contingent on maximum price determination by the Chamber of Regulation of Market Medicines (CMED). For the medication to enter the public Unified Health System (SUS), the National Commission for Incorporation of Technologies (Conitec) must issue an evaluation, followed by a formal decision from the Ministry of Health. Ministry officials attempted direct procurement talks with Gilead in July without reaching an agreement, though the manufacturer stated it intends to pursue ongoing discussions with the Brazilian government.
Efficacy Data and Clinical Mechanisms of Action
Lenacapavir functions by interfering with multiple steps of the viral capsid lifecycle, the protein shell that encapsulates the genetic material of human immunodeficiency virus. Phase III clinical trials formed the basis for recent regulatory clearances. In the Purpose 1 trial involving cisgender women, zero infections occurred among participants receiving the injectable drug. In the Purpose 2 trial, which evaluated cisgender men and gender-diverse individuals across international sites including Brazilian research centers, lenacapavir reduced HIV incidence by 96% compared against background infection rates, demonstrating an 89% higher efficacy than daily oral tenofovir disoproxil fumarate and emtricitabine regimens. Global health authorities, including the World Health Organization (WHO), incorporated the product into combination prevention guidelines in July 2025. Clinicians emphasize that the therapeutic is not a vaccine and demands rigorous baseline testing; medical personnel must confirm negative HIV status prior to every six-month injection to mitigate viral resistance risks associated with administering the drug during acute, undetected infection phases.
Advocacy, Patent Debates, and Regional Exclusions
The PAHO arrangement follows extensive advocacy from civil society organizations and public health authorities. In October 2024, Gilead granted voluntary licenses to six generic drugmakers to supply lenacapavir to 120 low- and middle-income nations, omitting Brazil and most Latin American territories from the arrangement. The Brazilian National Health Council subsequently issued a formal repudiation of the corporate decision, noting the country’s active participation in the Purpose 2 trial. The council recommended that federal authorities evaluate compulsory licensing frameworks, colloquially termed patent breaking, if commercial costs impeded public sector acquisition.
Future Outlook and Public Health Integration
The introduction of long-acting injectable prevention modalities addresses adherence barriers and social stigmas linked to daily pill consumption. However, clinical implementation relies on resolving complex procurement negotiations between state buyers and pharmaceutical holders.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*